Douglas G. McNeel, MD, PhD, University of Wisconsin Carbone Cancer Center, University of Wisconsin, Madison, WI, outlines the results of a pre-clinical study exploring the combination of antigen-specific vaccination and targeted radionuclide therapy in a murine prostate model. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.
